The IV antimicrobial tigecycline, indicated for the treatment of various infections, targets and destroys leukemia stem cells by cutting off the cell’s energy production.
A monoclonal antibody that disrupts the activation of osteoclasts increased bone-metastasis-free (BMF) survival in men with prostate cancer in a recent large trial.
Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.
People with advanced non-small cell lung cancer tumors expressing high levels of epidermal growth factor receptor are more likely to benefit when cetuximab (Erbitux) is used with chemotherapy.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
NSAIDs may be associated with lower colorectal cancer mortality among postmenopausal women, particularly in those who use these agents for longer periods of time before a diagnosis is made.
People with cancer who are being treated with antineoplastic agents should undergo routine testing for thyroid abnormalities.
Combining fludarabine with alemtuzumab significantly increases progression-free survival and prolongs the lives of patients with previously treated chronic lymphocytic leukemia.
Disease-free and overall survival significantly improved among women with HER2-positive breast cancer when 1 year of adjuvant trastuzumab was added to their treatment regimen.